Adaptate Biotherapeutics
Takeda is a global digital biopharmaceutical company dedicated to creating healthy lives for people worldwide through innovative research and development. With over 240 years of history, Takeda focuses on accelerating the transformation of research outcomes into breakthrough medicines and therapies to benefit patients globally and create social value.
Industries
Nr. of Employees
small (1-50)
Adaptate Biotherapeutics
Products
Gut-selective monoclonal antibody therapy for inflammatory bowel disease
A biologic therapy developed for moderate-to-severe ulcerative colitis and Crohn's disease, supported by large global Phase III trial programs evaluating induction and maintenance of clinical response and endoscopic outcomes.
Gene therapy product for a hereditary bleeding disorder
A gene therapy development program intended as a one-time or limited-administration treatment for a hereditary bleeding disorder, with reported local regulatory authorization activities and commercialization collaborations.
Oral DPP-4 inhibitor therapy and fixed-dose combinations for Type 2 diabetes
Oral DPP-4 inhibitor class therapy and fixed-dose combination formulations developed for glycemic control in adults with Type 2 diabetes, supported by extensive global clinical programs and cardiovascular safety studies.
Gut-selective monoclonal antibody therapy for inflammatory bowel disease
A biologic therapy developed for moderate-to-severe ulcerative colitis and Crohn's disease, supported by large global Phase III trial programs evaluating induction and maintenance of clinical response and endoscopic outcomes.
Gene therapy product for a hereditary bleeding disorder
A gene therapy development program intended as a one-time or limited-administration treatment for a hereditary bleeding disorder, with reported local regulatory authorization activities and commercialization collaborations.
Oral DPP-4 inhibitor therapy and fixed-dose combinations for Type 2 diabetes
Oral DPP-4 inhibitor class therapy and fixed-dose combination formulations developed for glycemic control in adults with Type 2 diabetes, supported by extensive global clinical programs and cardiovascular safety studies.
Services
Design and operation of multi-center clinical programs including pivotal Phase II/III trials, protocol development, regional enrollment and centralized statistical analysis.
Coordination of independent safety governance structures for clinical programs including data monitoring committees and expert safety review panels.
Preparation and management of regulatory dossiers and interactions with major health authorities to secure marketing authorizations and manage labeling.
Commercial production, in-country warehousing and logistics operations to support local market supply, including trade company operations to import products from global manufacturing locations.
Post-marketing safety monitoring and adverse event reporting infrastructure to support regulatory compliance and risk management.
Negotiation and execution of co-promotion and commercialization agreements and local market access strategies, including integration of acquired assets and sales teams.
Design and operation of multi-center clinical programs including pivotal Phase II/III trials, protocol development, regional enrollment and centralized statistical analysis.
Coordination of independent safety governance structures for clinical programs including data monitoring committees and expert safety review panels.
Preparation and management of regulatory dossiers and interactions with major health authorities to secure marketing authorizations and manage labeling.
Commercial production, in-country warehousing and logistics operations to support local market supply, including trade company operations to import products from global manufacturing locations.
Post-marketing safety monitoring and adverse event reporting infrastructure to support regulatory compliance and risk management.
Negotiation and execution of co-promotion and commercialization agreements and local market access strategies, including integration of acquired assets and sales teams.
Expertise Areas
- Global clinical trial management and statistical analysis
- Clinical safety monitoring and independent data oversight
- Cardiovascular outcomes and long-term safety trials
- Biologics development and translational medicine
Key Technologies
- Large-scale randomized controlled trials (Phase II/III)
- Cardiovascular outcomes trial methodology
- DPP-4 inhibitor therapeutic class (oral metabolic agents)
- Monoclonal antibody therapeutics
News & Updates
Takeda announced positive results from two pivotal Phase 3 studies of Oveporexton (TAK-861) for treating type 1 narcolepsy in July 2025.
Takeda China and Xinye Medical jointly announced the approval of 信玖凝® (波哌达可基注射液), China's first gene therapy for Hemophilia B, in April 2025.
Takeda's application for the listing of injection Apadase α in China was officially accepted in April 2025.
Important interim analysis results of the Early Crohn's Disease study were released at ECCO 2025 in February 2025, showing high remission rates and improved quality of life.
Takeda's three new drugs for type 2 diabetes, NESINA, OSENI, and KAZANO, received FDA approval in January 2013.
Takeda announced positive results from two pivotal Phase 3 studies of Oveporexton (TAK-861) for treating type 1 narcolepsy in July 2025.
Takeda China and Xinye Medical jointly announced the approval of 信玖凝® (波哌达可基注射液), China's first gene therapy for Hemophilia B, in April 2025.
Takeda's application for the listing of injection Apadase α in China was officially accepted in April 2025.
Important interim analysis results of the Early Crohn's Disease study were released at ECCO 2025 in February 2025, showing high remission rates and improved quality of life.
Takeda's three new drugs for type 2 diabetes, NESINA, OSENI, and KAZANO, received FDA approval in January 2013.